linjc16/ctgov huggingface dataset:
World Health Organization Disability Assessment Schedule (WHODAS-II) for Patients With Symptomatic Lumbar Disc Herniation

Study Overview
=================
Brief Summary
-----------------
The main purpose of this study is to determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule), as well as to analyze its correlation with symptomatic lumbar disc herniation (Visual Analog Scale, VAS), disability (Spanish version of the Roland Morris Questionnaire, RMQ), fear avoidance beliefs and attitudes (Spanish version of the FAB Questionnaire, FABQ) and quality of life (SF-12). Measurements will be taken at baseline and 6 days later (day 7).

Official Title
-----------------
WHODAS-II for Patients With Symptomatic Lumbar Disc Herniation

Conditions
-----------------
Lumbar Disc Herniation

Intervention / Treatment
-----------------
* Other: WHODAS II


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients seen for symptomatic lumbar disc herniation Radiated pain concordant with nerve root With or without motor restriction Able to read and write Signed the informed consent form Exclusion Criteria: Central nervous system pathology (with or without treatment) Diagnosis of rheumatic inflammatory disease or fibromyalgia Red flags for underlying systemic disease Criteria for diagnosis of symptomatic spinal stenosis Symptoms suggesting saddle anesthesia, cauda equina, loss of sphincter tone or paraparesis Motor deficit that progresses or does not improve in 6 weeks

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: 1<br>Measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule) | Other: WHODAS II<br>* To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurement characteristics of WHODAS-II |  | At baseline and at 7 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between WHODAS-II and VAS, RMQ, FABQ and SF-12 in symptomatic lumbar herniated disc |  | At baseline and at 7 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
symptomatic, lumbar disc herniation, disability, fear avoidance beliefs, quality of life
The Effect of Back Muscles Activation on Idiopathic Scoliosis Using Surface Electromyography

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the effect of back muscle activations on idiopathic scoliosis

Detailed Description
-----------------
Design: Prospective study Setting: hospital rehabilitation department Intervention: Participants were asked to walk with a surface electromyography(EMG) attached to their back muscles. After repeating the same process with different leg lengths discrepancy (0cm, 0.5cm, 1cm), participants are compared the main outcome measures. Main outcome measures: surface electromyography(EMG)

Official Title
-----------------
The Effect of Back Muscles Activation on Idiopathic Scoliosis Using Surface Electromyography

Conditions
-----------------
Idiopathic Scoliosis

Intervention / Treatment
-----------------
* Behavioral: gait with leg length discrepancy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy children (5 to 12 years old) Exclusion Criteria: Children with leg length discrepancy over 0.5cm Children complaining of acute low back pain Children with spinal scoliosis Children with cerebral palsy, muscle paralysis, polio, congenital spinal abnormalities Children who underwent spinal surgery

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Healthy children (5 to 12 years old)<br> | Behavioral: gait with leg length discrepancy<br>* After attaching the surface electromyography(EMG) to bilateral back muscles, participants walk at a comfortable speed. The investigators will evaluate the effects of leg length discrepancy on the back muscle activation during gait.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| surface electromyography | surface muscle contraction of bilateral back muscles bilateral spinal muscles on T6, T12, L3 bilateral quadratus lumborum muscles bilateral iliopsoas muscles | 20 minutes |
Oral Ginkgo Biloba and Narrow Band UVB in the Treatment of Vitiligo

Study Overview
=================
Brief Summary
-----------------
Vitiligo is a common chronic skin disease with 1-4% prevalence. It has a significant psychosocial impact on patients and society. Different treatment modalities with variable success rates are available. Phototherapy is among the successful treatments but gives modest results. Some reports documented the usefulness of Ginkgo Biloba (GB) when used alone in Vitiligo treatment.

Detailed Description
-----------------
Adding GB to phototherapy, especially the most commonly used one; Narrow-Band UVB (NBUVB) might give better results than using either one alone. This might improve repigmentation as well as patients' quality-of-life. (QOL). This will be a prospective double-blind randomized controlled clinical trial. One-hundred-sixty Vitiligo patients will be randomly divided into 2 groups( 80 patients per group). One group will receive oral GB (2 tablets of 60 mgs twice daily) with NBUVB twice weekly. The other group will receive placebo tablets( identical in size, shape and color) to GB twice daily with NBUVB twice weekly. Both groups will be treated for 6 months. Standard protocol of phototherapy will be used for both groups. Our aim here is to see whether adding GB to NBUVB will lead to better repigmentation than placebo or not.

Official Title
-----------------
Oral Ginkgo Biloba and Narrow Band UVB in the Treatment of Vitiligo : A Randomized Double - Blind Placebo Controlled Trial

Conditions
-----------------
Vitiligo

Intervention / Treatment
-----------------
* Dietary Supplement: GINGKO BILOBA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any Vitiligo patient (age 12 years and above) with non-segmental Vitiligo. Body surface area (BSA) involvement ≥ 3%. Exclusion Criteria: Unable to consent Any topical, systemic or phototherapy for Vitiligo in the previous 2 months. Pregnancy, breast feeding. Liver or kidney disease. Epilepsy Bleeding disorder or anticoagulant treatment

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Dietary Supplement: GINGKO BILOBA|MEMOREX 60 MG BID|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Repigmentation (more than 50% from baseline) as the primary outcome |  | 3,6 and 9 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality-of-life - as secondary outcome . |  | 3,6 and 9 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
phototherapy, Gingko biloba, repigmentation
Magnetic Resonance Imaging of Brain Development in Autism

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate brain development in autism by longitudinally assessing children with autism, as well as typically developing controls, using advanced MR techniques. We will use longitudinal diffusion tensor imaging (DTI) measures to investigate the protracted development of long-range white matter fibers in autism. In addition, we will investigate the effect of autism risk genes on brain development.

Official Title
-----------------
Magnetic Resonance Imaging of Brain Development in Autism

Conditions
-----------------
Autism

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged 6 - 18 years at initial MRI Inclusion criteria for subjects with autism 1) DSM-IV (APA, 1994) diagnosis of autism, according to ADI-R interview Inclusion criteria for controls no DSM-IV (APA, 1994) diagnosis, according to DISC interview no scores in the clinical range on the Child Behavior Checklist (CBCL) and Teacher Rating Form (TRF) IQ > 70 Exclusion Criteria: major illness of the cardiovascular, the endocrine, the pulmonal or the gastrointestinal system presence of metal objects in or around the body (pacemaker, dental braces) history of or present neurological disorder for individuals over 12 years of age: legal incompetence, defined as the obvious inability to comprehend the information that is presented by the investigator and is outlined in the Information letter and on which the decision to participate in the study is to be based

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Magnetic Resonance Imaging, Diffusion Tensor Imaging
Attenuation Imaging in Hepatic Steatosis

Study Overview
=================
Brief Summary
-----------------
For obese and normal-weight children, the investigators assess the diagnostic performance of attenuation imaging (ATI) in the detection of hepatic steatosis in children.

Official Title
-----------------
Noninvasive Assessment of Hepatic Steatosis by Using Attenuation Imaging in Children

Conditions
-----------------
Hepatic Steatosis, Obesity, Childhood, Ultrasonography

Intervention / Treatment
-----------------
* Diagnostic Test: Attenuation imaging in ultrasonography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI of 85th percentile or less Exclusion Criteria: congenital anomaly including heart, intestine, kidney acute hepatitis congenital hepatic anomaly

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Obesity<br>BMI of 95 th percentile or more | Diagnostic Test: Attenuation imaging in ultrasonography<br>* Attenuation imaging in ultrasonography<br>|
| Normal weight<br>BMI of 85 th percentile or less | Diagnostic Test: Attenuation imaging in ultrasonography<br>* Attenuation imaging in ultrasonography<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic performance of attenuation imaging | The diagnostic performance of attenuation imaging in US in the detection of hepatic steatosis | through study completion, an average of 1 year |
Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy

Study Overview
=================
Brief Summary
-----------------
Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severely Active Psoriatic Arthritis Subjects with Inadequate Response to Disease Modifying anti-Rheumatic Drug Therapy

Official Title
-----------------
Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy

Conditions
-----------------
Arthritis, Psoriatic

Intervention / Treatment
-----------------
* Drug: adalimumab
* Drug: placebo for adalimumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Moderate to severe PsA Inadequate response to DMARD therapy Corticosteroid stable dose <=10 mg QD DMARDs must have been taken for 3 months and stable dose for 4 weeks MTX maximum dose = <=30 mg/week Active chronic plaque PS or documented history of chronic plaque PS Exclusion Criteria: No other active skin disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: A<br> | Drug: adalimumab<br>* 40 mg adalimumab eow Week 0 - Week 12<br>* Other names: Humira;|
| Placebo Comparator: B<br> | Drug: placebo for adalimumab<br>* placebo eow Week 0 - Week 12<br>* Other names: placebo;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ACR20 |  | Week 12 | 
| Adverse Events |  | Throughout the Study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ACR50/70 |  | Week 12 | 
| Modified Psoriatic Arthritis Response Criteria |  | Week 12 | 
| Multiple QOL Assessments |  | Week 12 | 
| Physicians Global Assessment for Psoriasis |  | Week 12 |
Influence of Thoracic Epidural Anesthesia on Skin Sympathetic Activity and Heart Rate Variability

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to evaluate the impact of epidural anesthesia on sympathetic activity in surgical patients. The study investigates whether a segmental sympathetic block can be determined and can be correlated to level of the sensoric blockade.

Official Title
-----------------
Influence of Thoracic Epidural Anesthesia on Skin Sympathetic Activity and Heart Rate Variability in Surgical Patients

Conditions
-----------------
Abdominal Surgery, Abdominothoracic Surgery

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: elective surgery combined anesthesia with thoracic epidural anesthesia 8 (Th6-9 Body-mass-index < 30 Exclusion Criteria: Fever, Hypothermia, SIRS Microangiopathy Neuropathy Sensomotoric deficits

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hemodynamic parameters |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Level of sensoric block |  |  | 
| skin temperature |  |  |
Use of MigraineBoxTM Head and Neck Cooling Bath for Treatment of Primary Headache in the Emergency Department

Study Overview
=================
Brief Summary
-----------------
MigraineBoxTM is a simple, contoured cooling bath for the head and neck. Effectiveness of MigraineBoxTM will be studied in primary headaches in the emergency department. The user simply reclines his/her head and neck into this device that has contours that support the head and neck. Luke warm water is filled into the MigraineBoxTM before use and then a frozen insert is placed inside. This will gradually cool the water surrounding the patient's head and theoretically provide headache relief.

Official Title
-----------------
Use of MigraineBoxTM Head and Neck Cooling Bath for Treatment of Primary Headache in the Emergency Department

Conditions
-----------------
Primary Headache

Intervention / Treatment
-----------------
* Device: MigraineBoxTM


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-85 years old Benign headache Physician intends to treat headache pain in the ED with either droperidol, prochlorperazine, or a parenteral narcotic Exclusion Criteria: Unable to provide informed consent Headache due to trauma, subarachnoid hemorrhage, meningitis, intracerebral bleed, cranial tumor, sinusitis, dental pathology, temporomandibular joint dysfunction, glaucoma, or systemic infection Known renal impairment Known hepatic impairment A history of coronary artery disease, peripheral vascular disease, or cerebrovascular disease Perforated ear drum Pregnant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Primary Headache<br>Treatment with MigraineBoxTM | Device: MigraineBoxTM<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from Baseline in Pain Level | Patients will be asked to complete a 100 mm visual analog scale and a four point Likert scale concerning their pain. | Baseline, 30 minutes, 60 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from Baseline in Nausea | Patients will be asked to complete a 100 mm visual analog scale concerning their level of nausea. | Baseline, 30 minutes, 60 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Primary headache, Headache, MigraineBox
Study of Pituitary Size and Function in Familial Dwarfism of Sindh

Study Overview
=================
Brief Summary
-----------------
OBJECTIVES: I. Assess pituitary size and anatomic configuration by magnetic resonance imaging (MRI) in 4 affected dwarfs in the province of Sindh, Pakistan. II. Evaluate ultradian growth hormone (GH) secretory patterns in 4 affected dwarfs.

Detailed Description
-----------------
PROTOCOL OUTLINE: Pituitary size and anatomy and growth hormone response are evaluated. All patients undergo MRI of the pituitary fossa on day 1. On day 2, homozygous patients receive a slow infusion of normal saline with blood sampling every 10 minutes.

Conditions
-----------------
Growth Hormone Deficiency

Participation Criteria
=================
Eligibility Criteria
-----------------
Familial Dwarfism of Sindh Severe short stature but proportionate without dysmorphic features Normal body size and weight at birth Bone age is severely delayed Puberty is somewhat delayed (age 15-16) Fertility present in at least 3 dwarfs

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
endocrine disorders, growth hormone deficiency, rare disease
Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether sutent (sunitinib)is effective in preventing tumor recurrence in patients with high risk bladder cancer who have previously had chemotherapy and cystectomy (bladder removal). A 4 month supply of the drug is given to patients beginning 2-3 months after bladder removal. The patients are followed up to 2 years.

Official Title
-----------------
Phase II Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy

Conditions
-----------------
Urothelial Carcinoma, Bladder Cancer

Intervention / Treatment
-----------------
* Drug: Sunitinib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologic diagnosis of bladder carcinoma (>50% urothelial carcinoma) Prior treatment with at least one cycle of platin-based neoadjuvant chemotherapy Prior treatment with radical cystectomy revealing pT3NxM0 or pTanyN+M0 ECOG performance status of 0-1 (Appendix 2). No evidence of metastases within 4 weeks of registration Adequate organ and marrow function obtained within 14 days of registration Exclusion Criteria: Severe or uncontrolled acute or chronic medical or psychiatric condition Prior antiangiogenic therapy Prior pelvic radiation for bladder cancer

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Continuous Daily Dosing of Sunitinib<br> | Drug: Sunitinib<br>* Sunitinib 37.5 mg daily X 16 weeks<br>* Other names: Sutent;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disease Free Survival | 2-year disease free survival | 2- year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sunitinib, bladder neoplasm, adjuvant treatment, disease free survival, cystectomy